MedDataX Logo

Measuring the Incidence of Hospital Readmissions Based on Adverse Drug Events

NCT ID: NCT02074085

Last Updated: 2014-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An ADE is defined as harm caused by a drug or the inappropriate use of a drug. Retrospective record reviews in several countries have shown that anticoagulants frequently lead to hospital readmissions. In this study a hospital readmission is defined as an admission to the emergency department of the Jessa hospital. The objective of this study is to determine the incidence of one week and 30-day readmissions caused by (preventable) ADE's due to anticoagulants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incidence of Readmissions ADE's Due to Anticoagulants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who received an anticoagulant on their last day of admission
2. Patients who were readmitted within 30 days
3. Patients who were diagnosed using the pathology registration of the emergency department of the Jessa hospital

Exclusion Criteria

1. Patients who didn't receive an anticoagulant on their last day of admission
2. Patients who were not readmitted within 30 days
3. Patients who were not diagnosed using the pathology registration of the emergency department of the Jessa hospital
4. Patients with missing data
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jessa Hospital

OTHER

Sponsor Role collaborator

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

prof. dr. Neree Claes

prof. dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martijn Droogmans, pharmacist

Role: STUDY_CHAIR

Jessa Hospital

Kristel Marquet, drs

Role: STUDY_CHAIR

Hasselt University

Janne Theuwissen, pharmacist

Role: STUDY_CHAIR

Jessa Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jessa Ziekenhuis

Hasselt, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kristel Marquet, Drs.

Role: CONTACT

Phone: 3211268531

Email: [email protected]

Martijn Droogmans, Ap.

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kristel Marquet, drs

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14.05/APO14.01

Identifier Type: -

Identifier Source: org_study_id